摘要
目的:探究慢性萎缩性胃炎采取莫沙必利联合瑞巴派特治疗的临床疗效。方法:研究对象选取2016年7月—2018年7月期间在我院治疗的80例慢性萎缩性胃炎患者,按随机数字表法分成对照组(40例)与观察组(40例),对照组行单纯莫沙必利治疗,观察组在对照组基础上联合使用瑞巴派特治疗,比较两组临床疗效、治疗前后胃黏膜炎症积分与胃黏膜炎症病理积分及胃相关指标[胃泌素-17(Gastrin,G-17)、胃蛋白酶Ⅰ(Pepsin,PGI)、降钙素基因相关肽(Calcitonin gene related peptide,CGRP)、表皮生长因子(Epidermal growth factor,EGF)]。结果:观察组治疗后总有效率高于对照组,差异有统计学意义(P<0.05);两组患者治疗后,胃黏膜炎症积分与胃黏膜炎症病理积分均低于治疗前,且观察组较对照组低,差异有统计学意义(P<0.05);两组患者治疗后G-17、PGI、CGRP均高于治疗前,表皮EGF低于治疗前,且观察组治疗后G-17、PGI、CGRP高于对照组,EGF低于对照组,差异有统计学意义(P<0.05)。结论:慢性萎缩性胃炎采取莫沙必利联合瑞巴派特治疗,可提高临床疗效,降低炎症反应,改善胃相关指标。
Objective: To investigate the clinical effect of mosapride combined with ribapide in the treatment of chronic atrophic gastritis. Methods: 80 patients with chronic atrophic gastritis treated in our hospital from July 2016 to July 2018 were randomly divided into control group (40 cases) and observation group (40 cases). The observation group was treated with repapet on the basis of the control group. The clinical efficacy of the two groups was compared. The scores of gastric mucosal inflammation and the pathological score of gastric mucosal inflammation were compared before and after treatment (gastrin-17, PGI, CGRP, EGF). Results: The total effective rate of the observation group was higher than that of the control group (P<0.05);the scores of gastric mucosal inflammation and gastric mucosal inflammation pathology in the two groups after treatment were lower than those before treatment, and the observation group was lower than that in the control group (P <0.05);the G-17, PGI and CGRP in the two groups after treatment were higher than those before treatment, and the EGF in the epidermis was lower than that before treatment, and the observation group. After treatment, G-17, PGI and CGRP were higher than those in the control group, and EGF was lower than those in the control group (P<0.05). Conclusion: Mosapride combined with rebamipide can improve clinical efficacy, reduce inflammatory response and improve gastric related indicators in patients with chronic atrophic gastritis.
作者
程涛
CHENG Tao(Henan Shangqiu Municipal traditional Chinese Medicine Hospital, Henan Shangqiu 476000, China)
出处
《药品评价》
CAS
2019年第6期39-41,共3页
Drug Evaluation
